KZR

Kezar Life Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.510
-0.020
-0.44%
After Hours: 4.510 0 0.00% 16:00 09/25 EDT
OPEN
4.540
PREV CLOSE
4.530
HIGH
4.585
LOW
4.410
VOLUME
172.83K
TURNOVER
--
52 WEEK HIGH
9.79
52 WEEK LOW
2.180
MARKET CAP
208.62M
P/E (TTM)
-2.9949
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 09/18 11:30
INO, BKR, KODK and AHT among after-hours movers
Gainers: [[JAX]] +14%. [[KZR]] +10.3%. [[AHT]] +8%. [[KODK]] +7.9%. [[OM]] +5%.Losers: [[INO]] -3.8%. [[BTU]] -3.7%. [[EPRT]] -3.2%. [[BKR]] -3%. [[MYO]] -2.8%.
Seekingalpha · 09/17 21:44
Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today highlighted data from the Phase 1b portion of the MISSION study demonstrating safety, tolerability and early efficacy signals
Business Wire · 09/17 21:01
Encouraging lupus data lifts Kezar Life Sciences, up 9% after hours
Kezar Life Sciences (KZR) is up 9% after hours in reaction to data from the Phase 1b portion of the Phase 1/2 MISSION study evaluating lead candidate KZR-616 in patients with systemic
Seekingalpha · 09/17 20:52
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
Benzinga · 09/17 11:59
Kezar Life Sciences (KZR) Investor Presentation - Slideshow
The following slide deck was published by Kezar Life Sciences, Inc. in conjunction with this event.
Seekingalpha · 09/11 21:46
Mixed shelf roundup - healthcare
The following healthcare companies have filed for mixed shelf offerings:Citius Pharmaceuticals (CTXR): $100M.Flexion Therapeutics (FLXN): $300M.SCYNEXIS (SCYX): $200M.Kezar Life Sciences (KZR): $200M.
Seekingalpha · 09/11 20:41
Kezar Life Sciences to Present at The Myositis Association International Annual Patient Conference and the Pan-American Congress of Rheumatology
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced company presentations and participation at upcoming patient and medical conferences.
Business Wire · 09/10 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KZR. Analyze the recent business situations of Kezar Life Sciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KZR stock price target is 14.67 with a high estimate of 18.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 108
Institutional Holdings: 24.81M
% Owned: 53.63%
Shares Outstanding: 46.26M
TypeInstitutionsShares
Increased
25
3.92M
New
38
3.19M
Decreased
21
2.41M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Jean-Pierre Sommadossi
President/Chief Scientific Officer/Director
Christopher Kirk
Chief Executive Officer/Director
John Fowler
Chief Financial Officer/Secretary
Marc Belsky
Senior Vice President
Vassiliki Economides
Other
Noreen Henig
Independent Director
Franklin Berger
Independent Director
Graham Cooper
Independent Director
Jason Dinges
Independent Director
Elizabeth Garner
Independent Director
Michael Kauffman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About KZR
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small molecule therapeutics to treat autoimmune disorders, cancer, and malignant diseases. Its therapies target protein homeostasis. Its lead development program is KZR-616. KZR-616 is a selective small molecule inhibitor of the immunoproteasome. Its second program focuses on small-molecule modulators of the protein secretion pathway. Its protein secretion program is focused on the areas of oncology, inflammation and immune-oncology.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Kezar Life Sciences Inc stock information, including NASDAQ:KZR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KZR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KZR stock methods without spending real money on the virtual paper trading platform.